Literature DB >> 28975603

Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.

Koji Matsuo1,2, Muneaki Shimada3, Satoshi Yamaguchi4, Hiroyuki Kanao5, Toru Nakanishi6, Toshiaki Saito7, Shoji Kamiura8, Takashi Iwata9, Mikio Mikami10, Toru Sugiyama11.   

Abstract

This study seeks to identify risk factors associated with ovarian metastasis and to characterize a population with minimum risk of ovarian metastasis in young women with stage IB-IIB cervical cancer. This was a nation-wide multicenter retrospective study in Japan examining consecutive cases of surgically-treated women with clinical stage IB-IIB cervical cancer who had oophorectomy at radical hysterectomy (n = 5,697). Multivariable analysis was performed to identify independent risk factors for ovarian metastasis. Ovarian metastasis was seen in 70 (1.2%, 95% confidence interval 0.9-1.5) cases. In the entire cohort, adenocarcinoma, lympho-vascular space invasion, uterine corpus tumor invasion, and pelvic/para-aortic nodal metastases remained independent risk factors for ovarian metastasis (all, adjusted-p < 0.05). In a sensitivity analysis of 3,165 women aged <50 years (ovarian metastasis, 1.0%), adenocarcinoma, parametrial tumor involvement, uterine corpus tumor involvement, and pelvic/para-aortic nodal metastases remained independent risk factors for ovarian metastasis (all, adjusted-P < 0.05). In the absence of these five risk factors (representing 46.1% of women aged <50 years), the incidence of ovarian metastasis was 0.14%. With the presence of adenocarcinoma alone (representing 18.9% of women aged <50 years), the incidence of ovarian metastasis was 0.17% and was not associated with increased risk of ovarian metastasis compared to the subgroup without any risk factors (p = 0.87). In conclusion, nearly two thirds of women aged <50 years with clinical stage IB-IIB cervical cancer had no risk factor for ovarian metastasis or had adenocarcinoma alone: these subgroups had ovarian metastasis rates of around 0.1% and may be a candidate population for ovarian conservation at surgical treatment.
© 2017 UICC.

Entities:  

Keywords:  cervical cancer; early stage; ovarian metastasis; radical hysterectomy; risk factor

Mesh:

Year:  2017        PMID: 28975603     DOI: 10.1002/ijc.31084

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer.

Authors:  Koji Matsuo; Muneaki Shimada; Keiichiro Nakamura; Yuji Takei; Kimio Ushijima; Toshiyuki Sumi; Tatsuru Ohara; Hideaki Yahata; Mikio Mikami; Toru Sugiyama
Journal:  Eur J Surg Oncol       Date:  2019-02-18       Impact factor: 4.424

2.  Association of Radical Hysterectomy Surgical Volume and Survival for Early-Stage Cervical Cancer.

Authors:  Koji Matsuo; Muneaki Shimada; Satoshi Yamaguchi; Maki Matoda; Toru Nakanishi; Fumitaka Kikkawa; Masahide Ohmichi; Aikou Okamoto; Toru Sugiyama; Mikio Mikami
Journal:  Obstet Gynecol       Date:  2019-06       Impact factor: 7.623

3.  Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer.

Authors:  Koji Matsuo; Muneaki Shimada; Harushige Yokota; Toyomi Satoh; Hidetaka Katabuchi; Shoji Kodama; Hiroshi Sasaki; Noriomi Matsumura; Mikio Mikami; Toru Sugiyama
Journal:  Oncotarget       Date:  2017-11-15

4.  Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IB-IIB cervical cancer.

Authors:  Koji Matsuo; Muneaki Shimada; Tsuyoshi Saito; Kazuhiro Takehara; Hideki Tokunaga; Yoh Watanabe; Yukiharu Todo; Ken Ichirou Morishige; Mikio Mikami; Toru Sugiyama
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

5.  Generation of uniform-sized multicellular tumor spheroids using hydrogel microwells for advanced drug screening.

Authors:  Jong Min Lee; Da Yeon Park; Letao Yang; Eun-Joong Kim; Christian D Ahrberg; Ki-Bum Lee; Bong Geun Chung
Journal:  Sci Rep       Date:  2018-11-21       Impact factor: 4.379

6.  Study on value of ultrasonic elastography in diagnosis of clinical staging of cervical cancer and efficacy evaluation of radiotherapy.

Authors:  Yingying Zhang; Yuanyuan Yan; Yuejie Yang
Journal:  Oncol Lett       Date:  2019-03-26       Impact factor: 2.967

Review 7.  Diagnosis and Management of Adenocarcinoma in Situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations.

Authors:  Deanna Teoh; Fernanda Musa; Ritu Salani; Warner Huh; Edward Jimenez
Journal:  Obstet Gynecol       Date:  2020-04       Impact factor: 7.623

8.  Phase 1/2 study of concurrent chemoradiotherapy with weekly irinotecan hydrochloride for advanced/recurrence uterine cancer: A multi-institutional study of Kansai Clinical Oncology Group.

Authors:  Satoshi Takeuchi; Haruo Kuroboshi; Taisuke Mori; Kimihiko Ito; Eiji Kondo; Tsutomu Tabata; Yoshio Itani; Ryuji Kawaguchi; Kyosuke Takeuchi; Toshinori Soejima; Ryohei Sasaki
Journal:  Chin J Cancer Res       Date:  2020-04       Impact factor: 5.087

9.  Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival.

Authors:  Koji Matsuo; Muneaki Shimada; Satoshi Yamaguchi; Junzo Kigawa; Hideki Tokunaga; Tsutomu Tabata; Junichi Kodama; Kei Kawana; Mikio Mikami; Toru Sugiyama
Journal:  J Clin Med       Date:  2019-01-30       Impact factor: 4.241

10.  Ovarian metastasis in women with cervical carcinoma in stages IA to IIB: A systematic review and meta-analysis.

Authors:  Yu Fan; Meng-Yao Wang; Yi Mu; Si-Ping Mo; Ai Zheng; Jin-Ke Li
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.